



PRODUCT: Adakveo® (crizanlizumab-tmca)

COMPANY: Novartis Pharmaceuticals Corporation

THERAPEUTIC AREA & INDICATION:

Treatment to lower frequency of recurrent vaso-occlusive crises associated with severe vascular system pain for conditions like sickle cell anemia

ABOUT THE PRODUCT

Adakveo is the first and only FDA-approved, monthly targeted medicine that has been shown to reduce the annual rate of sickle cell pain crises to 1.63 vs 2.98 (equivalent to -45%) and the annual rate of days hospitalized to 4 vs 6.87 (-42%). In the SUSTAIN trial, IRRs (occurring during/within 24 hours of infusion) were observed in two (3%) patients treated with Adakveo 5 mg/kg. Post-marketing cases of IRRs, including severe pain events requiring hospitalization, have been reported. The most common side effects (incidence ≥10%) include nausea, joint pain, back pain, stomach-area (abdominal) pain or tenderness, and fever.